These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10859441)

  • 21. The significance of abdominal straining in men with lower urinary tract symptoms.
    Reynard JM; Peters TJ; Lamond E; Abrams P
    Br J Urol; 1995 Feb; 75(2):148-53. PubMed ID: 7531591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The reliability of the frequency-volume chart in assessing lower urinary tract symptoms.
    Yap TL; Cromwell DA; Brown C; Emberton M; van der Meulen J
    BJU Int; 2007 Jul; 100(1):111-5. PubMed ID: 17552958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The use of desmopressin as an alternative in the treatment of nycturia in patients with benign prostatic hyperplasia (BPH)].
    Granados Loarca EA; Garat Barredo JM; Villavicencio Mavrich H
    Actas Urol Esp; 1999 Jan; 23(1):56-9. PubMed ID: 10089634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interactions between prostate volume, filling cystometric estimated parameters, and data from pressure-flow studies in 565 men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Eckhardt MD; van Venrooij GE; Boon TA
    Neurourol Urodyn; 2001; 20(5):579-90. PubMed ID: 11574935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nocturia and polyuria in men referred with lower urinary tract symptoms, assessed using a 7-day frequency-volume chart.
    Matthiesen TB; Rittig S; Mortensen JT; Djurhuus JC
    BJU Int; 1999 Jun; 83(9):1017-22. PubMed ID: 10368248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between prostatic urethral angle and bladder outlet obstruction index in patients with lower urinary tract symptoms.
    Ku JH; Ko DW; Cho JY; Oh SJ
    Urology; 2010 Jun; 75(6):1467-71. PubMed ID: 19962734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ICS-'BPH' Study: the psychometric validity and reliability of the ICSmale questionnaire.
    Donovan JL; Abrams P; Peters TJ; Kay HE; Reynard J; Chapple C; De La Rosette JJ; Kondo A
    Br J Urol; 1996 Apr; 77(4):554-62. PubMed ID: 8777617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
    Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
    BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study.
    Yokoyama T; Kumon H; Nasu Y; Takamoto H; Watanabe T
    Int J Urol; 2006 Jul; 13(7):932-8. PubMed ID: 16882058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of intermittency in men with lower urinary tract symptoms.
    Reynard J; Lim C; Abrams P
    Urology; 1996 Apr; 47(4):491-6. PubMed ID: 8638356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Etiology of nocturia and clinical efficacy of naftopidil on nocturia in patients with benign prostatic hyperplasia--analysis of frequency volume charts].
    Masuda M; Nakayama K; Hiromoto Y; Hirokawa M; Satomi Y; Shiramizu M; Furuhata A; Ikeda A; Kawasaki C
    Hinyokika Kiyo; 2004 May; 50(5):309-14. PubMed ID: 15237482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The autonomic nervous system function in benign prostatic hyperplasia].
    Thor PJ; Mazur M; Furgała A; Worek M
    Folia Med Cracov; 2006; 47(1-4):79-86. PubMed ID: 18038615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association among the symptoms, quality of life and urodynamic parameters in patients with improved lower urinary tract symptoms following a transurethral resection of the prostate.
    Seki N; Yunoki T; Tomoda T; Takei M; Yamaguchi A; Naito S
    Neurourol Urodyn; 2008; 27(3):222-5. PubMed ID: 17580358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH.
    Nickel JC; Elhilali M; Vallancien G;
    BJU Int; 2005 Mar; 95(4):571-4. PubMed ID: 15705082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Home and office uroflowmetry for evaluation of LUTS from benign prostatic enlargement.
    Porru D; Scarpa RM; Prezioso D; Bertaccini A; Rizzi CA;
    Prostate Cancer Prostatic Dis; 2005; 8(1):45-9. PubMed ID: 15655566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of voiding disturbances in patients with LUTS and BPH at home and by episodic checks at an outpatient clinic.
    Satoh W; Nakada T
    Int Urol Nephrol; 1999; 31(2):211-20. PubMed ID: 10481966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment.
    Roehrborn CG; Kaminetsky JC; Auerbach SM; Montelongo RM; Elion-Mboussa A; Viktrup L
    BJU Int; 2010 Feb; 105(4):502-7. PubMed ID: 19732051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.